UK markets close in 5 hours 39 minutes
  • FTSE 100

    6,980.57
    -143.11 (-2.01%)
     
  • FTSE 250

    22,268.05
    -429.14 (-1.89%)
     
  • AIM

    1,238.87
    -19.03 (-1.51%)
     
  • GBP/EUR

    1.1613
    -0.0017 (-0.14%)
     
  • GBP/USD

    1.4135
    +0.0013 (+0.09%)
     
  • BTC-GBP

    39,373.32
    -1,811.20 (-4.40%)
     
  • CMC Crypto 200

    1,481.75
    -79.55 (-5.09%)
     
  • S&P 500

    4,188.43
    -44.17 (-1.04%)
     
  • DOW

    34,742.82
    -34.98 (-0.10%)
     
  • CRUDE OIL

    64.52
    -0.40 (-0.62%)
     
  • GOLD FUTURES

    1,838.10
    +0.50 (+0.03%)
     
  • NIKKEI 225

    28,608.59
    -909.71 (-3.08%)
     
  • HANG SENG

    28,013.81
    -581.89 (-2.03%)
     
  • DAX

    15,095.65
    -304.05 (-1.97%)
     
  • CAC 40

    6,267.94
    -118.05 (-1.85%)
     

Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2021 financial results on Wednesday, May 5, 2021, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the Company’s results in greater detail.

The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days.

Dial-in numbers for the conference call are as follows: US participants 877.698.7048 International participants 647.689.5448, conference ID: 3219208.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the US, Europe, and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops with partners diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional office locations in the US and Europe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005869/en/

Contacts

Clovis Investor Contacts:
Anna Sussman
303.625.5022
asussman@clovisoncology.com

Breanna Burkart
303.625.5023
bburkart@clovisoncology.com